FDMT (4D Molecular Therapeutics) Tariff Resilience Score: 7/10 (As of Jun. 28, 2026)


FDMT 4D Molecular Therapeutics Inc FDMT
55 GF Score
Price $11.60
GF Value $214.49
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is 4D Molecular Therapeutics Tariff Resilience Score?

4D Molecular Therapeutics FDMT +0.69% 55 Tariff Resilience Score is 7 as of Jun. 28, 2026. GuruFocus rates FDMT with a GF Score™ of 55/100 and a GF Value™ of $214.49 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,376 Biotechnology companies, 4D Molecular Therapeutics ranks better than 90.41% on this metric.

4D Molecular Therapeutics has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

4D Molecular Therapeutics has Biotech companies like 4D Molecular Therapeutics face limited direct tariff exposure. Its focus on R&D and intellectual property reduces dependency on physical goods. Historical impacts from tariffs have been minimal, and the company can leverage partnerships to mitigate risks.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes 4D Molecular Therapeutics might have Highly Resilient.

4D Molecular Therapeutics  (NAS:FDMT) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

4D Molecular Therapeutics Tariff Resilience Score Related Terms

FDMT vs KYTX, XOMA, OVID: Tariff Resilience Score Comparison

For the Biotechnology subindustry, 4D Molecular Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4D Molecular Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4D Molecular Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where 4D Molecular Therapeutics's Tariff Resilience Score falls into.


FDMT
55GF Score
4D Molecular Therapeutics Inc FDMT
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
4D Molecular Therapeutics (FDMT) has a Tariff Resilience Score of 7 as of Jun. 28, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, 4D Molecular Therapeutics ranks #132 out of 1376 companies in the Biotechnology industry, placing it in the top 9.6%.
Is 4D Molecular Therapeutics' Tariff Resilience Score too high?
4D Molecular Therapeutics' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. 4D Molecular Therapeutics' value of 7 is 75% above this industry median. Based on the distribution chart, 4D Molecular Therapeutics ranks #132 out of 1376 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, 4D Molecular Therapeutics has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 4D Molecular Therapeutics' Tariff Resilience Score compare to KYTX and XOMA?
According to the Biotechnology industry distribution chart, 4D Molecular Therapeutics ranks #132 out of 1376 companies for Tariff Resilience Score. This places 4D Molecular Therapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. 4D Molecular Therapeutics' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,376 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 4D Molecular Therapeutics's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 4D Molecular Therapeutics's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4D Molecular Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, 4D Molecular Therapeutics (FDMT) is currently considered Possible Value Trap. The stock's GF Value™ is $214.49, compared to a current price of $11.60 — trading 94.6% below its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. 4D Molecular Therapeutics' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For 4D Molecular Therapeutics (FDMT), the current Tariff Resilience Score is 7 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 4D Molecular Therapeutics (FDMT) Overvalued in 2026?

Based on GuruFocus' analysis, 4D Molecular Therapeutics stock appears to be undervalued. The current stock price of $11.60 is trading 94.6% below its estimated GF Value™ of $214.49. GuruFocus considers 4D Molecular Therapeutics to be Possible Value Trap.

Key valuation signals for FDMT:

  • Tariff Resilience Score: 7
  • GF Value™: $214.49 vs. price of $11.60 (94.6% below fair value)
  • GF Score™: 55/100 with 7 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1376)

No single metric tells the full story. See the FDMT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

4D Molecular Therapeutics Business Description

Address 5858 Horton Street, Suite 455, Emeryville, CA, USA, 94608
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
55GF Score

Get the complete analysis for FDMT

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.60
Price
$214.49
GF Value